Sumitomo Life Insurance Co. Buys Shares of 9,379 Stryker Corporation $SYK

Sumitomo Life Insurance Co. bought a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, Holdings Channel.com reports. The institutional investor bought 9,379 shares of the medical technology company’s stock, valued at approximately $2,953,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. VanderPol Investments L.L.C. raised its position in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares during the period. KCM Investment Advisors LLC boosted its position in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares during the period. Rossby Financial LCC grew its stake in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after acquiring an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its holdings in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares during the period. Finally, ICW Investment Advisors LLC lifted its position in shares of Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research analyst reports. Canaccord Genuity Group lowered their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Raymond James Financial set a $370.00 price target on shares of Stryker in a report on Friday, July 31st. BTIG Research dropped their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Finally, BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Trading Up 0.7%

NYSE:SYK opened at $329.86 on Friday. The company has a market capitalization of $126.52 billion, a P/E ratio of 34.18, a P/E/G ratio of 2.09 and a beta of 0.76. The stock’s 50 day moving average price is $326.99 and its 200 day moving average price is $332.64. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 665,370 shares of company stock worth $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.